Fusion proteins and their use in the diagnosis and treatment of leishmaniasis
US8771710B2 · kind B2 · utility
6Cited by
35References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 27, 2012 |
| Grant date | Jul 8, 2014 |
| Priority date | — |
| Expiry date | Jul 27, 2032 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/975
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.